Enlivex notifies availability of press release on FDA RMAT designation for Allocetra in knee osteoarthritis

Enlivex Ltd. announced that a press release regarding the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra in treating symptomatic age-related knee osteoarthritis in patients aged 64 and older is now available. The RMAT status may facilitate accelerated development through closer FDA engagement and priority review pathways. A Phase IIb trial involving 182 patients in the US and EU is underway, with top-line data expected by the end of Q2 2027.

Enlivex press release posted on FDA RMAT designation for Allocetra in symptomatic age-related knee osteoarthritis for patients aged 64+. * RMAT status may speed development via closer FDA engagement, accelerated approval pathways, priority review. * Phase IIb randomized trial targets 182 patients in the US, EU; top-line data expected by end-Q2 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9761022) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)